{"id":"NCT03631706","sponsor":"EMD Serono Research & Development Institute, Inc.","briefTitle":"M7824 Versus Pembrolizumab as a First-line (1L) Treatment in Participants With Programmed Death-ligand 1 (PD-L1) Expressing Advanced Non-small Cell Lung Cancer (NSCLC)","officialTitle":"An Adaptive Phase III, Multicenter, Randomized, Open-Label, Controlled Study of M7824 (Bintrafusp Alfa) Versus Pembrolizumab as a First-line Treatment in Patients With PD-L1 Expressing Advanced Non-small Cell Lung Cancer","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2018-10-01","primaryCompletion":"2021-06-07","completion":"2024-06-25","firstPosted":"2018-08-15","resultsPosted":"2022-06-29","lastUpdate":"2025-04-08"},"enrollment":304,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Non-small Cell Lung Cancer"],"interventions":[{"type":"DRUG","name":"M7824","otherNames":[]},{"type":"DRUG","name":"Pembrolizumab","otherNames":[]}],"arms":[{"label":"M7824","type":"EXPERIMENTAL"},{"label":"Pembrolizumab","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of the study is to evaluate the efficacy and safety of bintrafusp alfa (M7824) compared with pembrolizumab in participants with advanced NSCLC with high PD-L1-tumor expression, with no epidermal growth factor receptor (EGFR) mutation or anaplastic lymphoma kinase (ALK) translocation. The Phase III adaptive design allows for the option to recruit up to 584 patients based on pre-specified rules.","primaryOutcome":{"measure":"Progression-Free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors (RECIST Version 1.1) Assessed by Independent Review Committee (IRC)","timeFrame":"Time from randomization of study drug until the first documentation of PD or death, assessed approximately up to 746 days","effectByArm":[{"arm":"M7824","deltaMin":7,"sd":null},{"arm":"Pembrolizumab","deltaMin":11.1,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":7,"exclusionCount":5},"locations":{"siteCount":119,"countries":["United States","Argentina","Belgium","Brazil","Canada","China","France","Germany","Greece","Hong Kong","Italy","Japan","Netherlands","South Korea","Spain","Taiwan","Turkey (TÃ¼rkiye)","Ukraine"]},"refs":{"pmids":["23886301","37597750","38087967"],"seeAlso":["https://clinicaltrials.emdgroup.com/en/trial-details/?id=MS200647_0037","https://medical.emdserono.com/en_US/home.html"]},"adverseEventsSummary":{"seriousAny":{"events":90,"n":151},"commonTop":["Pruritus","Rash","Anaemia","Asthenia","Fatigue"]}}